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A B S T R A C T
Mosaic genome-wide paternal uniparental disomy (GW-pUPD) is a rarely recognised disorder. The phenotypic
manifestations of multilocus imprinting defects (MLIDs) remain unclear. We report of an apparently non-syndromic
infant with severe congenital hyperinsulinism (CHI) and diffuse pancreatic labelling by 18F*-DOPA-PET/CT leading
to near-total pancreatectomy. The histology was atypical with pronounced proliferation of endocrine cells com-
prising>70% of the pancreatic tissue and a small pancreatoblastoma. Routine genetic analysis for CHI was normal in
the blood and resected pancreatic tissue. At two years’ age, Beckwith-Wiedemann Syndrome (BWS) stigmata emerged,
and at five years a liver tumour with focal nodular hyperplasia and an adrenal tumour were resected. pUPD was
detected in 11p15 and next in the entire chromosome 11 with microsatellite markers. Quantitative fluorescent PCR
with amplification of chromosome-specific DNA sequences for chromosomes 13, 18, 21 and X indicated GW-pUPD. A
next generation sequencing panel with 303 SNPs on 21 chromosomes showed pUPD in both blood and pancreatic
tissue. The mosaic distribution of GW-pUPD ranged from 31 to 35% in blood and buccal swap to 74% in the resected
pancreas, 80% in a non-tumour liver biopsy, and 100% in the liver focal nodular hyperplasia and adrenal tumour.
MLID features included transient conjugated hyperbilirubinaemia and lack of macrosomia from BWS (pUPD6); and
behavioural and psychomotor manifestations of Angelman Syndrome (pUPD15) on follow-up. In conclusion, atypical
pancreatic histology in apparently non-syndromic severe CHI patients may be the first clue to BWS and multi-syn-
dromal CHI from GW-pUPD. Variations in the degree of mosaicism between tissues explained the phenotype.
1. Introduction
Beckwith-Wiedemann syndrome (BWS) most commonly occurs as a
sporadic, genetic disorder with typical features such as macroglossia,
abdominal wall defects, lateralized overgrowth, visceromegaly, and
increased risk of embryonal tumours (Weksberg et al., 2010; DeBaun
et al., 2000; Brioude et al., 2018). Hypoglycaemia is reported in
30–50% of all newborns with BWS, usually resolving spontaneously
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within the first month of life (Weksberg et al., 2010). However, a few
patients suffer from severe and prolonged congenital hyperinsulinism
(CHI) with hypoglycaemia necessitating intensive medical treatment
and eventual near-total pancreatectomy (Brioude et al., 2018; Toda
et al., 2017; Kalish et al., 2016). BWS is caused by various molecular
defects affecting the imprinted growth regulatory genes within the
11p15 region in 80% (Li et al., 1998; Choufani et al., 2010). Most
commonly, loss of methylation (LOM) of the imprinting centre
KCNQ1OT1 transcription start site differentially methylated region
(KCNQ1OT1: TSS-DMR, previously known as imprinting centre 2 (IC2))
is seen, affecting the maternally imprinted genes CDKN1C (p57/Kip2)
and KCNQ1OT1, followed by mosaic paternal uniparental disomy
(pUPD). pUPD is routinely detected by LOM of KCNQ1OT1: TSS-DMR
combined with gain of methylation (GOM) of the imprinting centre
H19/IGF2: intergenic DMR (H19/IGF2: IG-DMR, previously known as
imprinting centre 1 (IC1)), which enhances the expression of the pa-
ternally expressed growth promotor gene IGF2 and reduces expression
of maternally expressed and growth restraining H19. The combined
effect of altered H19/IGF2 expression cause increased growth as seen in
BWS. (Choufani et al., 2010; Eggermann et al., 2016).
Non-syndromal CHI is most frequently caused by mutations of the
KATP-channel genes ABCC8 or KCNJ11, which are situated on 11p15
(Stanley, 2016). In the pancreas, a diffuse, a focal, and atypical histo-
logical forms are seen. The focal form is characterized by a paternal
ABCC8 or KCNJ11 germline mutation combined with a somatic focal
loss of maternal 11p15, usually in a very small area of the pancreas
escaping conventional imaging, but detectable by 18F*-fluoro-dihy-
droxyphenylalanine (18F*-DOPA) PET/CT. In the focal lesion, im-
balance of imprinted genes with expression of paternal growth pro-
motor genes ,but lack of expression of maternal tumour suppressor
genes, results in overgrowth.
The histological features of the pancreas in BWS patients with
prolonged, severe CHI have been sparsely described (Laje et al., 2013;
Hussain et al., 2005). More recently, BWS patients with severe CHI
were found to have mosaic, somatic pUPD extending to the adjacent
KATP-channel genes on 11p15, unmasking an otherwise recessive, co-
existing paternal KATP-channel mutation (Kalish et al., 2016; Kocaay
et al., 2016; Calton et al., 2013). Rare BWS-spectrum patients show
multilocus imprinting defects (MLIDs) with evidence of mosaic pUPD in
other imprinted regions due to genome-wide pUPD (GW-pUPD), po-
tentially including pUPD6 (low birth weight, conjugated hyperbilir-
ubinaemia, transient neonatal diabetes); pUPD14 (Kagami-Ogata syn-
drome; psychomotor retardation, finger contractures, bell shaped
thorax); pUPD15 (Angelman Syndrome) and pUPD20 (pseudohypo-
parathyroidism) (Wilson et al., 2008; Kalish et al., 2013). However, the
phenotype correlation to MLIDs in BWS remains unclear (Brioude et al.,
2018). Phenotypic variations are hypothesised to reflect differences in
degree of mosaicism in different tissues and coexistence of paternal
mutations with recessive presentation in the UPD paternal cell line
(Wilson et al., 2008). To date, at least seven patients with GW-pUPD,
BWS-features and CHI have been reported (Wilson et al., 2008; Kalish
et al., 2013; Gogiel et al., 2013; Giurgea et al., 2006).
We report the case of a seemingly non-syndromic preterm infant
with severe CHI and mosaic GW-pUPD without KATP-channel muta-
tions, where follow-up revealed multi-syndromal CHI comprising BWS
with abdominal tumours and features of pUPD6 and pUPD15/
Angelman Syndrome.
2. Patient data
2.1. Clinical presentation at onset
The girl was the second child of healthy, non-related Caucasian
parents. The pregnancy was naturally conceived and normal up to
premature rupture of membranes and vaginal birth at gestational age
33 + 0 weeks in 2010. Birth weight was 2185 g (+0.2 SD), birth length
45 cm (+0.7 SD), head circumference 31.0 cm (+0.45 SD), Apgar
score 9/1, 10/5, 10/10 min. No dysmorphic features were noted. She
presented with blood glucose of 0.1 mmol/L at 2 h of age. The hy-
poglycaemia was promptly and adequately treated to avoid brain da-
mage. Intravenous (i.v.) glucose demands reached 15 mg/kg/min de-
spite simultaneous treatment with high doses of diazoxide, octreotide
and i.v. glucagon. At glucose 2.2 mmol/L without medication, p-insulin
was 105 (reference 12–77) pmol/L, C-peptide 4000 (reference
300–2400) pmol/L, confirming the diagnosis of hyperinsulinism. At
blood glucose 4.1 mmol/L during i.v. 50% glucose infusion, p-insulin
was haemolysed, but C-peptide was elevated to 2704 pmol/L and p-
proinsulin was exceptionally high;> 260 (reference 2–23) pmol/L. To
obtain normoglycemia, i.v. glucagon and i.v. glucose were required
despite diaxozide and octreotide treatment. An 18F*-DOPA-PET/CT
scan at 14 days of age showed DOPA uptake throughout the entire
pancreas suggestive of diffuse congenital hyperinsulinism
(Supplemental Fig. 1A). In retrospect, both the liver and the pancreas
were enlarged compared to an age-matched patient with mild, diffuse
CHI (Supplemental Fig. 1B). A near-total (90–95%) pancreatectomy
was performed as early as at 20 days of age. Enlargement of the pan-
creas and liver was observed at surgery. By frozen section microscopy,
diffuse hyperplasia of the islets of Langerhans was found. Information
about immunohistochemical staining is listed in Supplementary
Table 1.
2.2. Pancreatic histology and immunohistochemistry
The left-sided pancreatic resection specimen measured
10× 20×70mm. At microscopy, an increased number of endocrine
cells, arranged in islets and small clusters, as well as single endocrine
cells were observed throughout the pancreas (Fig. 1A). The endocrine
cells occupied more than 70% of the parenchyma. All endocrine cells
strongly expressed synaptophysin (Fig. 1B), and most of these cells were
positive for insulin, while cells positive for glucagon and somatostatin
were observed at the periphery of the islets. Acinar cells and small ducts
were observed at the periphery of the pancreatic lobules and between
the endocrine islets and cell clusters. When anti-p57/Kip2 was applied
for immunohistochemistry, a positive reaction of varying intensity was
seen in approximately 5% of the endocrine cells (Fig. 1C). The p57/
Kip2-positive endocrine cells were mainly found in small hot spot areas.
The exocrine tissue did not show any mentionable reaction. Control
experiments applying the antibody to a focal type of CHI did not show
expression of p57/Kip2.The entire resected pancreatic tissue showed
these changes (Supplemental Fig. 2A).The proliferative activity as-
sessed by Ki-67 was high, and the Ki-67 index reached 35% in hot spots.
Compared with five randomly selected specimens from our archive of
cases with the focal CHI, the density of nuclei in the endocrine lesion
was 3.994 nuclei per 0.4 mm2 in the BWS patient versus a mean of
2.513 nuclei per 0.4mm2 (range 1.759–3.544) in focal CHI.
In addition to the large endocrine lesion, a focus of pancreato-
blastoma measuring 3×1 mm was noted (Supplemental Fig. 2B).
Within the pancreatoblastoma, diffuse immunohistochemical expres-
sion of alfa-foetoprotein, cyclin D1 and cytokeratin CKAE1/AE3 was
found, and no expression of p63. Positivity for monoclonal carci-
noembryonic antigen was seen in the columnar cells lining the duct-like
structures. The squamoid nests in the pancreatoblastoma showed ab-
normal nuclear expression of beta-catenin. No overgrowth of exocrine
tissue was observed.
2.3. Postoperative clinical course and BWS
Postoperative complications included transient hyperglycaemia,
septicaemia, delayed establishment of enteral feeding, and transient
malabsorption. An abnormally long-standing necrotic umbilical cord
stump was resected at 41 days of age. The umbilicus was broad and
slightly elevated, but without intestinal herniation into the cord stump,
H.T. Christesen, et al. European Journal of Medical Genetics 63 (2020) 103632
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why BWS was not suspected.
From postoperative day 20, hypoglycaemia remitted, however
milder. During diazoxide treatment, p-insulin was suppressed, 7 and
4 pmol/L, respectively, at blood glucose 3.0 and 2.9 mmol/L; C-peptide
was in normal range, 188 and 202 pmol/L, but pro-insulin was still
surprisingly high, 90 and 94 pmol/L. At follow-up until eight years of
age, the hypoglycaemia was controlled with few exceptions of hy-
poglycaemia down to 2.8 mmol/L by diazoxide, long-acting release
octreotide and dietary long carbohydrates. Fasting proinsulin levels
were normalised along with p-insulin and C-peptide during treatment.
Mild hypertrophic cardiomyopathy with mild aortic stenosis and mitral
insufficiency were repeatedly found. Regarding syndromal features,
BWS was suspected due to left-sided hemihypertrophy, enlarged
umbilicus without herniation, and enlarged liver by age two years.
Repeat ultrasound investigations showed a hepatic process and a
transient pseudocyst in the pancreas. Routine BWS screens for cancer
were initially negative, but liver gamma glutamyl transferase was
mildly elevated and a biopsy showed focal adenomatous hyperplasia
(FNH) of the cystic liver process, which was resected at the age of 5½
years. The left kidney was enlarged, 11 cm long, with ill-defined border
between the cortex and medulla, but without tumour. By MRI, a 3 cm
right-sided adrenal tumour was found, leading to right-sided adrena-
lectomy at 6 years’ age. By histology, the adrenal tumour had high
mitotic activity, but uncertain potential of malignancy. The hemi-
hypertrophy accounted for 1–2 cm increased left leg length only at last
follow-up. Height equalled 0 SD, weight +1SD.
3. Methods
Candidate gene analyses were in 2010 performed by denaturing
high-performance liquid chromatography (dHPLC) with subsequent
Sanger sequencing (Christesen et al., 2007). A subsequent next gen-
eration sequencing (NGS) CHI panel analysis was performed on blood
and resected pancreatic tissue as previously described (Christiansen
et al., 2018). Methylation analysis of the 11p15 locus was performed by
MLPA (multiplex ligation-dependent probe amplification) analysis
using kit ME030-C3 from MRC-Holland (MRC-Holland, Amsterdam, the
Netherlands) following the manufacturer's instructions. The Coffalyser
program (MRC-Holland) was used for data analysis.
Analysis for UPD of chromosome 11 was performed by micro-
satellite analysis using 12 polymorphic markers (D11S1363, D11S4046,
D11S4146, D11S1760, D11S1338, D11S4149, D11S902, D11S4190,
D11S915, D11S904, D11S917, D11S4090). A standard PCR reaction
was performed using fluorescent tagged primers and taq gold poly-
merase. Products were analysed by capillary electrophoresis on an
ABI3130XL (Applied Biosystems, Foster City, CA, USA) and the
GeneMapper program (Applied Biosystems) were used for data analysis.
Quantitative fluorescence (QF)ePCR using kit QST*Rplusv2 (Elucigene,
Manchester, UK) comprising markers from chromosomes 13, 18, 21, X
and Y was carried out on DNA from blood from the patient and both
parents as an indication of GW-UPD. Furthermore, QF-PCR was per-
formed on DNA from pancreatic tissue from the patient. DNA extracted
from fresh liver (non-tumour and tumour) and adrenal tumour tissue
was subjected to high resolution whole-genome genotyping using the
CytoScan HD array (Thermo Fisher Scientific/Affymetrix) according to
standard methods. The Chromosome Analysis Suite (ChAS, Thermo
Fisher Scientific/Affymetrix) software was used to analyse CytoScan HD
array data for B-allele frequency (BAF).
Sequencing was performed with a targeted NGS panel on blood,
saliva and pancreatic tissue by use of the Agilent targeted sequence
capture method followed by sequencing on the Illumina HiSeq1500
NGS platform (Illumina Inc, San Diego, CA). The sequencing design of
the assay utilized designed oligonucleotides by use of Agilent
SureDesign to capture all exons, 5′- and 3′-UTR, and 50 kb into the 5′-
and 3′- UTR, and 50 kb into the flanking regions of the exons. A
SureSelectXT Reagent kit (Agilent Technolo-gies Denmark ApS,
Glostrup, Denmark) was used and run on a single lane using paired-end
sequencing at 2× 100 bp. The covered region included 303 SNPs in 36
genes situated on chr. 1–14,16-19,20–22,X; among these 18 CHI/β-cell-
related genes. The average coverage for the target regions was 127.7
reads.
The study was conducted in accordance with the Declaration of
Helsinki and national guidelines. Permission to collect data from the
patient record was acquired from the local Danish Research Ethics
Committee (reference no. 54947). The project was approved by the
Danish Data Protection Agency (journal no. 16/28242). The legal
guardians of the patient approved publication.
Fig. 1. Histological and immunochemical findings in pancreatic resection spe-
cimen from the patient. A) Increased numbers of endocrine cells arranged in
islets and clusters are seen (H&E). B) Serial section of the area shown in A,
demonstrating strong synaptophysin-positivity in the endocrine cells (sy-
naptophysin immunostaining). C) The endocrine lesion showed expression of
p57/Kip2 of varying intensity in approximately 5% of the endocrine cells, often
found in small hot spot areas (p57/Kip2 immunostaining).
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4. Results
4.1. Genetic analyses
Before the pancreatic surgery, rapid genetic analysis and MLPA
analysis of ABCC8 and KCNJ11 showed no indications of point muta-
tions, deletions or duplications. Activating insulin gene sequence var-
iants were initially suspected due to the extremely elevated p-proinsulin
compared to p-insulin. However, postoperative dHPLC analysis showed
no sequence variants affecting function in INS. Furthermore, no se-
quence variants affecting function were identified in the other CHI-
genes GLUD1, GCK, HNF1A, HNF4A. In the later NGS panel analysis, no
mutations were found in 18 CHI/β-cell-related genes in the blood or
pancreas, indicating no additional germline or somatic mutations re-
lated to CHI.
MLPA analysis for BWS showed LOM of KCNQ1OT1:TSS-DMR and
GOM of H19/IGF2:IG-DMR thus confirming the BWS diagnosis. Since
the conventional copy number MLPA analysis showed normal result,
UPD was suspected as the genetic mechanism. This was confirmed by
microsatellite analysis, which showed increased contribution of the
paternal allele of six informative markers (six markers were non-in-
formative; data not shown). Furthermore, whole chromosome 11 UPD
was detected. QF-PCR analysis of chromosomes 13, 18, 21, and X in
blood and pancreatic tissue indicated not only pUPD for chromosome
11, but GW-pUPD, Fig. 2. In blood, saliva and pancreatic tissue, pUPD
was detected in 303 SNPs distributed on 21 chromosomes, Fig. 3. The
mosaic distribution of GW-pUPD ranged from 31% in blood; 35% in
buccal swap, to 74% in the resected pancreas; and by BAF analysis 80%
in the non-tumour liver biopsy and 100% in the liver FNH and the
adrenal tumour, Fig. 4 and Supplemental Fig. 3.
4.2. GW-pUPD phenotype correlations
Because of the mosaic GW-pUPD, we searched for other possible
pUPD manifestations, including pUPD6, pUPD14, pUPD15, and
pUPD20. Regarding pUPD6, transient conjugated hyperbilirubinaemia
was noted in the neonatal period. The conjugated bilirubin peaked at
95 μmol/L by age 18 days and the conjugated fraction reached a
maximum of 71% (conjugated 68 μmol/L, non-conjugated 28 μmol/L)
by age 37 days. By ultrasound, the bile ducts were not dilated. In the
right part of the liver, the bile duct tree was less visible compared to the
left side, in retrospect suggesting segmental intrahepatic bile duct hy-
poplasia. No follow-up on this concern was done due to the transient
nature of the clinical manifestations. Other pUPD6 features were not
recorded, but may have been masked by the coexisting BWS with CHI.
No finger contractures were seen and a chest X-ray aged five years
showed normal configuration, which is why no indication of pUPD14
phenotype was present. Lastly, p-calcium and phosphate were normal,
indicating that no pUPD20 phenotype was present.
Psychomotor and neurological examinations by five years of age
showed a normal electroencephalogram and nerve conduction velocity
test, global Motor ABC-score equalled the 75th percentile, but left-sided
upper extremity ataxia was found and global balance score equalled the
25th percentile only. Fine motor score and ball skills equalled the
99.5th and 75th percentile, respectively. By standard paediatric neu-
rological examination identified a slight suspicion of left-sided ankle
spasticity and ½-1 year's retarded global psychomotor performance.
Other clinical features compatible withAngelman Syndrome included
short concentration span and hypermotoric behaviour, easy laughter,
smile and joyousness, delayed language development, a very marked
fascination of water, sleeping problems, heat intolerance and some
degree of swallowing disturbance, but no facial, head or palmar dys-
morfology. At latest follow-up eight years old, she was unable to read,
although letters were recognised.
5. Discussion
We present an exceptional patient with severe, persistent CHI as the
only presenting sign of BWS, remarkably elevated p-proinsulin levels,
atypical histological pancreatic features with endocrine cells com-
prising more than 70% of the parenchyma and a congenital pancrea-
toblastoma. Mosaic GW-pUPD was identified with highest degree of
74–80% pUPD in the pancreas and non-tumour liver biopsy, to 100% in
the liver FNH and the adrenal tumour. Clinical features of pUPD6 and
pUPD15/Angelman Syndrome were detected compatible with GW-
pUPD.
The phenotype of mosaic somatic gene alterations is expected to
vary according to the degree of mosaicism in affected tissue. Mosaicism
is especially frequent in the imprinting disorders of 11p15, BWS and
Silver-Russell Syndrome (Mackay and Temple, 2017). A broader
Fig. 2. QF-PCR analysis on DNA from blood and
pancreatic tissue indicating GW-pUPD. A) QF-PCR
analysis of DNA from blood. Only a subset of mar-
kers is shown, one marker located on the X-chro-
mosome (DXS6803), one marker located on chro-
mosome 13 (D13S634), one marker from
chromosome 18 (D18S535) and three markers from
chromosome 21 (D21S1435, D21S11, D21S1437).
Alleles marked with a “P” indicate the paternal al-
lele. B) QF-PCR analysis of DNA from pancreas
tissue. The same six markers are shown. Only the
paternal allele appears in DNA from pancreas
tissue.
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spectrum of BWS (BWSp) from isolated lateralized overgrowth to
classical BWS is now recognised, partly caused by variations in somatic
mosaicism (Brioude et al., 2018).
In BWS with CHI, pUPD has been found in most (26/28) patients
(Kalish et al., 2016), in contrast to approximately 20% in BWS in
general. When not associated with additional CHI-related gene muta-
tions, pancreatic islet cell overgrowth is suggested to be the
pathophysiological mechanism of the hyperinsulinism. However, this
has been regarded to lead to mild CHI only, in contrast to patients with
BWS plus a KATP-channel mutation (Kalish et al., 2016; Kocaay et al.,
2016). Our patient had no additional germline or somatic CHI gene
mutations, but a high mosaic degree of pUPD in the resected pancreas.
Moreover, a high β-cell number in the pancreas and an extremely in-
creased p-proinsulin compared to p-insulin showed evidence of severe
Fig. 3. Direct sequencing of 303 SNPs on 21 chromosomes in DNA from pacreatic tissue and blood, exemplified by the ABCC8 SNP rs1799859. NGS sequencing of
DNA by coverage (on top) and read pile-up (bottom) from formalin-fixed parafin-embedded pancreatic tissue (A) and blood (B). The mosaic distribution of GW-pUPD
was 74% in the pancreas and 31% in the blood.
H.T. Christesen, et al. European Journal of Medical Genetics 63 (2020) 103632
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hyperinsulinism due to β-cell overgrowth with hyperproduction of
proinsulin. Likewise, disproportionate hyperproinsulinaemia is a char-
acteristic finding in insulinoma patients with loss-of-function mutations
in the tumour suppressor gene MEN1 (Vezzosi et al., 2007). In contrast,
CHI from KATP-channel mutations typically shows insulin hypersecre-
tion, evidenced by a relative lower proinsulin:insulin ratio (Christesen
et al., 2001).
Severe neonatal CHI as the only presenting feature in BWS has to
our knowledge only been described once before by Hussain et al.
(2005), but in less details. In the report by Hussain et al., severe CHI
was seen and the β-cell KATP-channel function was altered despite no
detected mutations in ABCC8 or KCNJ11. A search for somatic KATP-
channel mutations was, however, not performed. Adachi et al. reported
a BWS patient with severe CHI and macrosomia from birth as the only
BWS features (Adachi et al., 2013). In the Kalish et al. cohort of BWS in
CHI patients, additional BWS stigmata were found in all patients at
birth. The number of BWS stigmata correlated significantly with the
mosaic percentage of pUPD in the blood (Kalish et al., 2016). In our
patient, the low variable mosaic degree of pUPD from 31 to 35% in the
blood and saliva to 74–100% in the pancreas, liver FNH and adrenal
tumour correlated well with the phenotype. The hypertrophic cardio-
myopathy is a common finding in CHI as a result of the anabolic effect
of foetal hyperinsulinism (Huang et al., 2013).
The pancreatic histology was atypical with some features re-
miniscent of both focal and diffuse CHI (Rahier et al., 2011; Ismail
et al., 2012; Kloppel et al., 1999). In contrast to focal CHI, our patient
showed increased endocrine cells throughout the pancreas in extreme
numbers, but did not show the typical confluence of islets of Langer-
hans often seen in classical focal CHI. Furthermore, expression of p57/
Kip2 was seen in approximately 5% of the endocrine cells in contrast to
focal CHI, where loss of maternal 11p15 leads to total absence of p57
expression in the lesion. Our findings are probably similar to the aty-
pical histological changes reported in less details in a few other BWS
patients with CHI (Laje et al., 2013; Hussain et al., 2005). Of note, the
association of an atypical endocrine pancreatic lesion at histology to-
gether with a congenital pancreatoblastoma as in our patient has only
been reported once before (Laje et al., 2013), but may serve as a clue for
BWS.
At follow-up, our patient developed BWS features and characteristic
abdominal tumours. Both CHI and abdominal tumours are seemingly
more frequent in the 14 reported BWS patients with GW-pUPD to date
(Wilson et al., 2008; Kalish et al., 2013; Inbar-Feigenberg et al., 2013;
Bertoin et al., 2015). Our finding of a skewed allele distribution with
74–100% pUPD in the resected pancreatic, liver and adrenal tissue
indicated that the hyperinsulinism and abdominal tumours reflected the
high degree of pUPD11, rather than other pUPD manifestations in these
tissues. It can be speculated that GW-pUPD patients are prone to a
higher degree of skewed allele distribution in abdominal tissues com-
pared to patients with BWS due to pUPD11.15 alone. Consistent with
the concept of GW-pUPD, where an androgenic 46, XY lineage is lethal
(Yamazawa et al., 2011), our and all other published patients were
females.
As resumed by Kalish et al. (2013), a few GW-pUPD BWS patients
display features of other syndromes associated with paternal UPD for
other chromosomes, notably UPD14, UPD15, UPD6 and UPD20. Due to
mosaicism, a phenotypic spectrum is to be expected. We found clear
behavioural and developmental features which could be associated
with pUPD15/Angelman Syndrome already at five years of age. We did
not assign any of these features with neurological complications to
hypoglycaemia, as this was prompt and adequately treated; neither to
the late preterm birth. One other study mentioned poor language and
unsteady gait as Angelman features in a 13-y-old girl with GW-pUPD
and BWS, CHI and 25% mosaicism for pUPD15 (Inbar-Feigenberg et al.,
2013), but no other Angelman features, and the cerebral damage due to
severe hypoglycaemia at birth was not discussed as an alternative
cause.
Lastly, transient neonatal conjugated hyperbilirubinaemia and sus-
picion of segmental intrahepatic bile duct hypoplasia were found in our
patient, compatible with pUPD6 (Kenny et al., 2009). Other features of
pUPD6 include low birth weight and transient neonatal diabetes. It is
likely that these features were counterbalanced by the BWS with CHI
phenotype, resulting in normal birth weight and hypoglycaemia,
leaving conjugated hyperbilirubinaemia as the only clear manifestation
of pUPD6.
In conclusion, GW-pUPD may present with severe CHI as the only
clear manifestation at birth, but with overt BWS including abdominal
tumours and features of pUPD6 (conjugated hyperbilirubinaemia) and
pUPD15 (Angelman Syndrome) at follow-up. The degree of mosaic
pUPD ranged from 31 to 35% in the blood to 74–100% in the resected
pancreas and adrenal and liver tumour, demonstrating that the phe-
notype of GW-pUPD depends on tissue-variations in the degree of mo-
saicism. In unexplained, seemingly non-syndromal severe CHI, identi-
fication of pUPD11p15 (both sexes) and eventual GW-pUPD (girls only)
will provide a basis for appropriate clinical follow-up regarding emer-
ging multi-syndromal features. We introduce the novel name multi-
syndromal CHI to shortly describe GW-pUPD with CHI as the dominant
and presenting feature. In patients with clinical suspicion of multi-
syndromal CHI, GW-pUPD analyses should be performed.
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